SCHEMBL2722883

SCHEMBL2722883

CCOc1ccccc1OC(=O)NCc1ccc(Cl)cc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.53
KMT2A Q03164 6/20 0.51
MEN1 O00255 5/20 0.51
POLB P06746 2/20 0.51
HTT P42858 2/20 0.51
MAPT P10636 2/20 0.51
GAA P10253 2/20 0.50
ALDH1A1 P00352 3/20 0.49
NPC1 O15118 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
LMNA P02545 1/20 0.49
ATM Q13315 3/20 0.48
HPGD P15428 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
KDM4E B2RXH2 1/20 0.47
RAB9A P51151 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15339799 0.88 MEN1 (0.56) FAAHKMT2AMEN1POLBHTT
SCHEMBL4437536 0.86 POLB (0.53) FAAHKMT2AMEN1POLBMAPT
SCHEMBL4438882 0.85 FAAH (0.58) FAAHKMT2AMEN1POLBMAPT
SCHEMBL2725301 0.84 FAAH (0.60) FAAHKMT2AMEN1POLBMAPT
SCHEMBL2734060 0.83 FAAH (0.53) FAAHKMT2AMEN1POLBMAPT
SCHEMBL2723278 0.81 FAAH (0.57) FAAHKMT2AMEN1POLBMAPT
SCHEMBL31321653 0.79 LMNA (0.57) KMT2AMEN1POLBMAPTALDH1A1
SCHEMBL3274554 0.77 NPC1 (0.65) FAAHKMT2AMEN1HTTGAA
SCHEMBL6333483 0.76 SMN1; SMN2 (0.69) KMT2AMEN1MAPTGAAALDH1A1
SCHEMBL2725306 0.76 CES2 (0.54) KMT2AMEN1POLBGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9249128-B2 Anti-cancer serine hydrolase inhibitory carbamates THE SCRIPPS RESEARCH INSTITUTE (US) 2016-02-02 US disclosed
US-9249128-B2 Anti-cancer serine hydrolase inhibitory carbamates THE SCRIPPS RESEARCH INSTITUTE (US) 2016-02-02 US disclosed
US-9249128-B2 Anti-cancer serine hydrolase inhibitory carbamates THE SCRIPPS RESEARCH INSTITUTE (US) 2016-02-02 US disclosed
US-20130281453-A1 ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES THE SCRIPPS RESEARCH INSTITUTE (US) 2013-10-24 US disclosed
US-20130281453-A1 ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES THE SCRIPPS RESEARCH INSTITUTE (US) 2013-10-24 US disclosed
US-20130281453-A1 ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES THE SCRIPPS RESEARCH INSTITUTE (US) 2013-10-24 US disclosed
EP-2632912-A2 ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES The Scripps Research Institute (US) 2013-09-04 EP disclosed
WO-2012058115-A2 ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES CRAVATT BENJAMIN (US) 2012-05-03 WO disclosed
WO-2012058115-A2 ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES CRAVATT BENJAMIN (US) 2012-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281453-A1 ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES AADAC, DDAH1, PRSS1 FAAH 58/4885KMT2A 684/4885MEN1 2343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.